differences in semaglutide and tirzepatide Comparing vs Semaglutide: Effects, Cost, Global Obesity and Wellness Care

Demand for GLP-1 alternatives has fueled an explosion of OTC products

In turn, this may exacerbate disparities

1.1 Limitations of Use: IMCIVREE is not indicated for the treatment of patients with the following conditions as IMCIVREE would not be expected to be effective: Obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC, PCSK1, or LEPR variants classified as benign or likely benign

The FDA has also raised concerns about unapproved GLP-1 products, including: Incorrect dosing or measurement Concentration differences between pharmacies Use of unapproved semaglutide salt forms Products containing too much or too little active ingredient Fraudulent or improperly labelled products Adverse events related to compounded injections Patients should confirm the pharmacy name, drug concentration, prescribed dose and measurement instructions before administering each shipment